OFI Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

OFI Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	$42K	Sell	400 -29	-7%	-$3.73K	﹤0.01%	1602
2015 Q2	$53K	Buy	429 +35	+9%	+$4.41K	﹤0.01%	1583
2015 Q1	$46K	Sell	394 -163	-29%	-$19.5K	﹤0.01%	1605
2014 Q4	$66K	Sell	557 -131	-19%	-$14.8K	﹤0.01%	1567
2014 Q3	$77K	Sell	688 -522	-43%	-$49.7K	0.01%	1532
2014 Q2	$115K	Buy	1,210 +156	+15%	+$10.9K	0.01%	1404
2014 Q1	$75K	Sell	1,054 -183	-15%	-$14.5K	0.01%	1514
2013 Q4	$92K	Sell	1,237 -7,687	-86%	-$535K	0.01%	1440
2013 Q3	$677K	Buy	8,924 +6,959	+354%	+$554K	0.07%	333
2013 Q2	$157K	Buy	+1,965	New	+$145K	0.02%	1019

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

OFI Advisors's VRTX Position: Q3 2015 in Review

OFI Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 6.8% in Q3 2015, selling an estimated $3.73K and leaving 400 shares worth $42K. The position accounts for ﹤0.01% of the portfolio, ranked #1602.

OFI Advisors first reported a position in VRTX in Q2 2013 and has held it in 10 quarters since. The position peaked at $677K in Q3 2013. 494 funds tracked by Wall St. Rank hold VRTX as of Q3 2015.

OFI Advisors held 400 shares of Vertex Pharmaceuticals worth $42K as of Q3 2015.
OFI Advisors sold 29 Vertex Pharmaceuticals shares in Q3 2015, an estimated $3.73K.
Vertex Pharmaceuticals made up ﹤0.01% of OFI Advisors's portfolio in Q3 2015, its #1602 holding.
OFI Advisors first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 10 quarters since.
OFI Advisors's Vertex Pharmaceuticals position peaked at $677K in Q3 2013.
494 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2015.

Based on OFI Advisors's 13F filing for Q3 2015, filed 13 Nov 2015.